Loss of the ssecks/gravin/akap12 gene results in prostatic hyperplasia

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5096-5103

  Akakura, Shin ^a   Huang, Changhui ^a   Nelson, Peter J ^b   Foster, Barbara ^a   Gelman, Irwin H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; PHOSPHATIDYLINOSITOL; UVOMORULIN; AKAP12 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE LOSS; GENETIC SUSCEPTIBILITY; GENETIC TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN DEPLETION; STAINING; ANIMAL; C57BL MOUSE; CROSS BREEDING; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MOLECULAR CLONING; MOUSE MUTANT; TRANSGENE;

A KINASE ANCHOR PROTEINS; ANIMALS; CELL CYCLE PROTEINS; CLONING, MOLECULAR; CROSSES, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTATIC HYPERPLASIA; TRANSGENES;

EID: 48549092597     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5619     Document Type: Article

References (46)

1. Nauert J, Klauck T, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffolding protein. Curr Biol 1997;7:52-62.
2. Lin X, Gelman IH. Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res 1997;57:2304-12.
3. Gelman IH. The role of the SSeCKS/Gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002;7:1797.
4. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with VEGF inhibition. Cancer Res 2006;66:5599-607.
5. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001;15:5644-51.
6. Gelman IH. Metastasis suppression by SSeCS/Gravin/AKAP12 through the inhibition of distal angiogenesis. In: Jackson P, editor. Developments in Metastasis Suppressors.Australia: Nova Publications; 2007.
7. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem 1996;271:2846-8.
8. Gelman IH, Tombler E, Vargas J, Jr. A role for SSeCKS, a major protein kinase C substrate with tumor suppressor activity, in cytoskeletal architecture, formation of migratory processes, and cell migration during embryogenesis. Histochem J 2000;32:13-26.
9. Nelson PJ, Moissoglu K, Vargas JJ, Klotman PE, Gelman IH. Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. J Cell Sci 1999;112:361-70.
10. Streb JW, Kitchen CM, Gelman IH, Miano JM. Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. J Biol Chem 2004;279:56014-23.
11. Erlichman J, Gutierrez-Juarez R, Zucker S, Mei XH, Orr GA. Developmental expression of the protein kinase C substrate/binding protein (clone 72/SSeCKS) in rat testis - identification as a scaffolding protein containing an A-kinase-anchoring domain which is expressed during late-stage spermatogenesis. Eur J Biochem 1999;263:797-805.
12. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
13. Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22:1495-503.
14. Shen MM, Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn 2003;228:767-78.
15. Ma X, Ziel-van der Made AC, Autar B, et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005;65:5730-9.
16. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78.
17. Abate-Shen C, Banach-Petrosky WA, Sun X, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003;63:3886-90.
18. Bai F, Pei XH, Pandolfi PP, Xiong Y. p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol 2006;26:4564-76.
19. Tao J, Wang HY, Malbon CC. Src docks to A-kinase anchoring protein gravin, regulating β2-adrenergic receptor resensitization and recycling. J Biol Chem 2007;282:6597-608.
20. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91:459-77.
21. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87.
22. Brawer MK. Prostatic intraepithelial neoplasia: a premalignant lesion. J Cell Biochem Suppl 1992;16G:171-4.
23. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30.
24. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9.
25. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004;22:307-12.
26. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
27. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-47.
28. Lin X, Nelson P, Gelman IH. Regulation of G→S progression by the SSeCKS tumor suppressor: control of cyclin D expression and cellular compartmentalization. Mol Cell Biol 2000;20:7259-72.
29. Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 2006;45:901-13.
30. Cohen SB, Waha A, Gelman IH, Vogt PK. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. Oncogene 2001;20:141-6.
31. Choi MC, Jong HS, Kim TY, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 2004;23:7095-103.
32. Yoon DK, Jeong CH, Jun HO, et al. AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett 2007;254:111-8. Epub 2007 Apr 17.
33. Camus A, Mesbah K, Rallu M, Babinet C, Barra J. Gene trap insertion reveals two open reading frames in the mouse SSeCKS gene: the form predominantly detected in the nervous system is suppressed by the insertion while the other, specific of the testis, remains expressed. Mech Dev 2001;105:79-91.
34. Klingbeil P, Frazzetto G, Bouwmeester T. Xgravin-like (Xgl), a novel putative a-kinase anchoring protein (AKAP) expressed during embryonic development in Xenopus. Mech Dev 2001;100:323-6.
35. Weiser DC, Pyati UJ, Kimelman D. Gravin regulates mesodermal cell behavior changes required for axis elongation during zebrafish gastrulation. Genes Dev 2007;21:1559-71.
36. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 1996;7:269-78.
37. Vidal A, Carneiro C, Zalvide JB. Of mice without pockets: mouse models to study the function of Rb family proteins. Front Biosci 2007;12:4483-96.
38. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
39. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
40. Pommery N, Henichart JP. Involvement of PI3K/Akt pathway in prostate cancer-potential strategies for developing targeted therapies. Mini Rev Med Chem 2005;5:1125-32.
41. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTENexpression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-92.
42. Gelman IH, Gao L. The SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via rhoa- and Cdc42-dependent pathways. Mol Cancer Res 2006;4:150-8.
43. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 2001;98:11563-8.
44. Hill R, Song Y, Cardiff RD, Van Dyke T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 2005;65:10243-54.
45. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996;56:1142-5.
46. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996;56:4150-3.